Welcome to our dedicated page for Prestige Consumer Healthcare SEC filings (Ticker: PBH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Prestige Consumer Healthcare's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Prestige Consumer Healthcare's regulatory disclosures and financial reporting.
Prestige Consumer Healthcare senior vice president Jose Luis Rosado reported receiving 3,426 shares of common stock on January 6, 2026, at a price of $0 per share, bringing his direct holdings to 3,436 shares.
The award represents restricted stock units that are scheduled to fully vest on January 6, 2030, indicating a long-term, equity-based component to his compensation aligned with the company’s future performance.
Prestige Consumer Healthcare executive Jose Luis Rosado filed an initial insider ownership report. As of January 6, 2026, he beneficially owns 10 shares of common stock, held directly. Rosado serves as SVP – Quality & Regulatory Affairs. No derivative securities are reported.
Prestige Consumer Healthcare Inc. officer Jeffrey Zerillo, Senior VP Operations, reported two open-market sales of company stock. On 11/28/2025, he sold 719 shares of common stock at $60 per share, leaving him with 42,329 shares beneficially owned afterward. On 12/01/2025, he sold an additional 281 shares at $60 per share, reducing his holdings to 42,048 shares.
The filing is a Form 4, which discloses changes in ownership by company insiders and confirms that Zerillo’s holdings remain directly owned after these transactions.
An affiliate of PBH has filed a Rule 144 notice to sell 281 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an indicated aggregate market value of $16,860.00. The filing shows that 48,084,010 shares of this class were outstanding at the time of the notice, providing a baseline for the issuer’s equity size.
The shares to be sold were originally acquired on 05/04/2023 through restricted stock vesting from the issuer as compensation, rather than a cash purchase. The seller, Jeffrey A. Zerillo, also sold 719 shares of common stock on 11/28/2025 for $43,140.00 during the prior three months, as disclosed in the same notice.
PBH has a holder planning to sell 719 shares of its common stock under Rule 144. The planned sale is through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 11/28/2025 and an aggregate market value of 43140.00.
The securities being sold were acquired through restricted stock vesting from the issuer on 05/02/2025 and 05/05/2025, in amounts of 673 and 46 shares as compensation. As context, the number of shares of PBH common stock outstanding is reported as 48084010.
Prestige Consumer Healthcare Inc. (PBH) director John E. Byom reported a sale of company stock. On 11/25/2025, he sold 3,000 shares of common stock at a price of $59.35 per share in a single reported transaction where multiple lots at the same price were combined. After this sale, he beneficially owns 51,594 shares, held directly. The filing is made on Form 4, which reports changes in the ownership of company equity by an insider who serves as a director.
PBH has a Form 144 filing indicating a planned sale of common stock by a shareholder. The notice covers up to 3,000 common shares to be sold through Fidelity Brokerage Services LLC on the NYSE, with an indicated aggregate market value of $178,050.00. The filing notes that 48,084,010 shares of the issuer’s stock are outstanding.
The shares to be sold were acquired through restricted stock vesting from the issuer as compensation: 2,295 shares vested on 08/01/2024 and 705 shares vested on 08/06/2025. The approximate date of the planned sale is 11/25/2025. The filer represents that they are not aware of any undisclosed material adverse information about the issuer’s operations.
Ariel Investments, LLC filed a Schedule 13G reporting beneficial ownership of 3,594,959 shares of Prestige Consumer Healthcare (PBH) common stock, representing 7.3% of the class as of 09/30/2025.
The firm reports sole voting power over 3,214,409 shares and sole dispositive power over 3,594,959 shares, with no shared voting or dispositive power. Ariel states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Ariel’s adviser clients have the right to receive dividends or sale proceeds from the reported securities, and none of the clients holds an economic interest exceeding 5% of PBH’s outstanding common stock.
Prestige Consumer Healthcare (PBH) reported Q2 results. Total revenues were $274.1 million for the three months ended September 30, 2025, down 3.4% year over year. Net income was $42.2 million and diluted EPS was $0.86. Gross margin was 55.3%, slightly lower than 55.5% a year ago as International margins softened. Operating income was $79.7 million, while the effective tax rate rose to 38.9% primarily due to a new state tax presence.
For the six months, revenues were $523.6 million (down 5.0%) and operating cash flow reached $136.5 million. The company repurchased $109.8 million of stock at an average price of $70.34, ending with $119.1 million in cash. Long‑term debt remained $1.0 billion, with $190.0 million of unused capacity on the 2012 ABL Revolver. North American sales declined on Eye & Ear Care shortages, while Gastrointestinal grew; International revenue was roughly flat with mixed category performance.
Prestige Consumer Healthcare (PBH) announced financial results for the fiscal quarter and six months ended September 30, 2025. The company furnished a press release detailing the results as Exhibit 99.1 and an investor presentation as Exhibit 99.2.
Management began using the investor presentation on November 6, 2025 and may use it during the fiscal year ending March 31, 2026. The materials in Items 2.02 and 7.01 and Exhibits 99.1 and 99.2 are furnished, not filed, and are not subject to Section 18 liabilities unless specifically stated otherwise.